N′-(α-aminoacyl)- and N′-α-(N-alkylamino)acyl derivatives of vancomycin and eremomycin: II. Antibacterial activity of N′-(α-aminoacyl)- and N′-α-(N-alkylamino)acyl derivatives of vancomycin and eremomycin

Journal of Antibiotics

Volumn 60, Issue 4, 2007, Pages 245-250

  Plattner, Jake J ^b   Chu, Daniel ^b   Mirchink, Elena P ^a   Isakova, Elena B ^a   Preobrazhenskaya, Maria N ^a   Olsufyeva, Evgenia N ^a   Miroshnikova, Olga V ^a   Printsevskaya, Svetlana S ^a  

^a GAUSE INSTITUTE OF NEW ANTIBIOTICS   (Russian Federation)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Antibacterial activity; Eremomycin; SAR; Semisynthetic derivatives of antibacterial glycopeptides; Vancomycin

Indexed keywords

AMIDE; AMINO ACID DERIVATIVE; ANTIBIOTIC AGENT; EREMOMYCIN; EREMOMYCIN DERIVATIVE; GLYCINE; N' (N 4 OCTYLOXYBENZYLGLYCYL) VANCOMYCIN; N' (N ALPHA 4 OCTYLOXYBENZYL LEVO ALANYL) VANCOMYCIN; UNCLASSIFIED DRUG; VANCOMYCIN; VANCOMYCIN DERIVATIVE; ANTIINFECTIVE AGENT; DRUG DERIVATIVE; GLYCOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG STRUCTURE; ENTEROCOCCUS; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; CHEMISTRY; DRUG EFFECT; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; MICROBIOLOGICAL EXAMINATION;

MUS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GLYCOPEPTIDES; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 34547231694     PISSN: 00218820     EISSN: None     Source Type: Journal    
DOI: 10.1038/ja.2007.29     Document Type: Article

References (7)

1. Preobrazhenskaya MN, Olsufyeva EN. Patent on glycopeptides of vancomycin family and their derivatives as antimicrobials: January 1999-May 2003. Expert Opinion on Therapeutic Patents 14: 141-173 (2004)
2. Allen NE, LeTourneau DL, Hobbs, Jr., JN. The role of hydrophobic side chain as determinants of antibacterial activity of semisynthetic glycopeptide antibiotics. J Antibiot 50: 677-684 (1997)
3. Preobrazhenskaya MN, Olsufyeva EN, Miroshnikova OV, Printsevskaya SS, Chu D, Plattner J. Studies of antibacterial activity of N′-aminoacyl derivatives of vancomycin and eremomycin containing a hydrophobic substituent at amino acyl residue. Abstracts of Papers of 45th Intersci Conf on Antimicrob. Agents Chemother, F-1227, 190, Washington (2005)
4. Judice JK, Pace JL. Semi-synthetic glycopeptide antibacterials. Bioor Med Chem Lett 13: 4165-4168 (2003)
5. Preobrazhenskaya MN, Olsufyeva EN, Miroshnikova OV, Printsevskaya SS, Plattner JJ, Chu D. N′-(α-Aminoacyl)-and N′-α-(N- alkylamino)acyl derivatives of vancomycin and eremomycin. I. Synthesis of N′-(α-aminoacyl)- and N′-α-(N-alkylamino)acyl derivatives vancomycin and eremomycin by selective acylation of the amino sugar of the disaccharide branch. J Antibiot 60: 235-244 (2007)
6. Pavlov AY, Preobrazhenskaya MN, Malabarba A, Ciabatti R, Colombo L. Mono and double modified teicoplanin aglycon derivatives on the amino acid No. 7; Structure-activity relationship. J Antibiot 51: 73-81 (1998).
7. Pavlov AY, Miroshnikova OV, Printsevskaya SS, Olsufyeva EN, Preobrazhenskaya MN, Goldman RC, Branstrom AA, Baizman ER, Longley CB. Synthesis of hydrophobic N′-mono and N′,N″-double alkylated eremomycins inhibiting the transglycosylation sage of bacterial cell wall biosynthesis. J Antibiot 54: 455-459 (2001)